Literature DB >> 18329831

Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons.

O'neil W Guthrie1, Ha-Sheng Li-Korotky, John D Durrant, Carey Balaban.   

Abstract

Genomic DNA is a high-affinity target for the antineoplastic molecule cisplatin. Cell survival from cisplatin DNA damage is dependent on removal of cisplatin-DNA adducts by nucleotide excision repair (NER) pathways. The rate-limiting steps in the NER pathways are DNA damage identification and verification. These steps are accomplished by xeroderma pigmentosum complementation group C and A (XPC and XPA) and RNA polymerase II. Unlike RNA polymerase II, XPC and XPA have no known cellular function beyond DNA repair. Cisplatin is known to damage spiral ganglion neurons at the basal coil of the cochlea therefore it was posited that cisplatin may target their DNA and mobilize XPC and XPA. Female Fisher344 rats were given two, four day cycles of cisplatin (2mg/kg) or saline, separated by a 10day rest period. A 2 x 3 x 2 factorial design, consisting of two treatment conditions (cisplatin and saline treatment), three survival times (5, 19 and 22 days) and two analysis methods (quantitative RT-PCR and immunohistochemistry) was employed to evaluate the expression and distribution of XPC and XPA. Quantitative RT-PCR revealed statistically significant differences in cochlear XPC and XPA mRNA levels after cisplatin treatment at all times except day 22 for XPA. Immunohistochemistry revealed that a proportion ( approximately 50%) of spiral ganglion neurons in control rats showed cytoplasmic expression of XPC and XPA. After cisplatin treatment, a similar proportion ( approximately 50%) of spiral ganglion neurons showed increased nuclear expression of XPC and XPA, which appears to represent translocation from the cytoplasm. Basal coil spiral ganglion neurons translocated XPC and XPA at later treatment cycles and with less magnitude than apical coil neurons after cisplatin treatment. Therefore, it is suggested that cisplatin treatment induces nuclear translocation of NER proteins among spiral ganglion neurons and that this nuclear translocation is less efficient at the base relative to the apex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329831     DOI: 10.1016/j.heares.2008.01.013

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  13 in total

1.  Real-time quantification of Xeroderma pigmentosum mRNA from the mammalian cochlea.

Authors:  O'neil W Guthrie; Franklin A Carrero-Martínez
Journal:  Ear Hear       Date:  2010-10       Impact factor: 3.570

2.  Preincision complex-I from the excision nuclease reaction among cochlear spiral limbus and outer hair cells.

Authors:  O'neil W Guthrie
Journal:  J Mol Histol       Date:  2008-11-01       Impact factor: 2.611

Review 3.  Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.

Authors:  Corné J Kros; Peter S Steyger
Journal:  Cold Spring Harb Perspect Med       Date:  2019-11-01       Impact factor: 6.915

Review 4.  An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Toxicol Lett       Date:  2015-06-20       Impact factor: 4.372

5.  Noise Stress Induces an Epidermal Growth Factor Receptor/Xeroderma Pigmentosum-A Response in the Auditory Nerve.

Authors:  O'neil W Guthrie
Journal:  J Histochem Cytochem       Date:  2017-01-05       Impact factor: 2.479

6.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 7.  DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions.

Authors:  Ella W Englander
Journal:  DNA Repair (Amst)       Date:  2013-05-16

8.  Mutations in Cockayne Syndrome-Associated Genes (Csa and Csb) Predispose to Cisplatin-Induced Hearing Loss in Mice.

Authors:  Robert N Rainey; Sum-Yan Ng; Juan Llamas; Gijsbertus T J van der Horst; Neil Segil
Journal:  J Neurosci       Date:  2016-04-27       Impact factor: 6.167

Review 9.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

10.  Coenzyme Q10 plus Multivitamin Treatment Prevents Cisplatin Ototoxicity in Rats.

Authors:  Laura Astolfi; Edi Simoni; Filippo Valente; Sara Ghiselli; Stavros Hatzopoulos; Milvia Chicca; Alessandro Martini
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.